04/09/2026
Inova’s Advanced Lung Disease Program once again has demonstrated its commitment to leading-edge treatments for complex lung conditions with some very promising early results published in The New England Journal of Medicine.
Congratulations to Steven Nathan, MD, Medical Director and Schar Chair, Advanced Lung Disease and Lung Transplant as first author, and Christopher King, MD, Associate Medical Director and contributing author, on this landmark study.
Subsequently, results of a parallel study, which included sites in the US and Canada has been released which confirm the findings. Together, these studies provide a compelling case for a fourth approved drug for Idiopathic Pulmonary Fibrosis, a progressive, life-limiting disease for which existing treatments provide only modest benefit.
A special shoutout to the Advanced Lung Disease Research team at Inova which enrolled a large number of patients into the North America study, and Dr. Nathan, as chair of the steering committee for the TETON program, for his deep involvement in the study’s design and ex*****on.
👉 Learn more: https://bit.ly/4mkiFFD
👉 Inova Lung Services: https://bit.ly/3ZrClh4